CCT3 overexpression might affect the progression of multi-ple myeloma through the JAK/STAT3 pathway. The JAK2/STAT3 pathway has been considered a promising target for chemotherapeutic interference ascribed to its persistent activation in human carcinomas. CCT3 may be a new molecular target to overcome cisplatin resistance of LUAD patients. The gene discussed is CCT3; the disease is carcinoma.